Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: J Immunol. 2022 Dec 1;209(11):2149–2159. doi: 10.4049/jimmunol.2200324

FIGURE 2. TriVax-immunized CoH mice exhibit blunted CD8 and CD4 T cell expansion.

FIGURE 2.

A. Experimental Design – SPF and CoH B6 mice were immunized with either B8R- or 2W1S-TriVax. Blood was collected on days 7, 8, 14, and 28 after immunization to determine the frequency of (B) B8-specific CD8 T cells or (C) 2W1S-specific CD4 T cells of total CD8 or CD4 T cells, respectively. On day 28, spleens were also isolated to determine the frequency and number of (D) B8R-specific CD8 T cells or (E) 2W1S-specific CD4 T cells. F-G. SPF and CoH mice were immunized with either B8R or 2W1S peptide mixed with either (F) Complete Freund’s Adjuvant (CFA) or (G) Alhydrogel. Spleens were collected 7 days later, and the number of B8R-specific CD8 T cells or 2W1S-specific CD4 T cells were determined. Data in B-G are representative of at least 2 technical replicates. n = 4–7 mice/group. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, **** p ≤ 0.001.